A 52-year-old man with a 3-year history of dilated cardiomyopathy presents with dyspnea on exertion, orthopnea, and peripheral edema. Echocardiography confirms heart failure with reduced ejection fraction (HFrEF, EF 28%). He is euvolemic after diuretic optimization and ACE inhibitor therapy. The cardiologist plans to initiate a β-blocker with proven mortality benefit in HFrEF. The structure marked **C** in the diagram represents agents with combined α and β-blocking activity. Which of the following β-blockers should be initiated at low dose and titrated every 2–4 weeks to target dose for mortality reduction in this patient?

Explanation

## Why Carvedilol is right Carvedilol is one of only THREE β-blockers with proven mortality benefit in HFrEF (COPERNICUS and CAPRICORN trials), alongside metoprolol succinate (extended-release) and bisoprolol. It combines non-selective β-blockade with α1-blocking activity, producing both negative chronotropic/inotropic effects AND vasodilation—ideal for HFrEF pathophysiology. The marked structure **C** (combined α + β agents) includes carvedilol, and it is the guideline-directed choice for HFrEF. Dosing starts low (3.125 mg BD) and titrates every 2–4 weeks to target (25 mg BD) to minimize transient negative inotropy while achieving ~35% mortality reduction. (KD Tripathi 9e Ch 10; Harrison 21e Ch 252) ## Why each distractor is wrong - **Labetalol**: Although it shares the combined α + β-blocking profile with carvedilol (structure **C**), labetalol lacks proven mortality benefit in HFrEF. Its primary role is acute hypertensive emergency management and pregnancy-related hypertension, not chronic HFrEF therapy. Starting labetalol at 100 mg BD is also not standard for HFrEF titration. - **Pindolol**: This agent has intrinsic sympathomimetic activity (structure **D**, not **C**), which limits its benefit in HFrEF. ISA-containing β-blockers do not reduce mortality in HFrEF and are avoided in this population due to their partial agonist properties. - **Propranolol**: A non-selective β1 + β2 blocker (structure **B**, not **C**) without α-blocking activity and without proven mortality benefit in HFrEF. Non-selective agents increase the risk of bronchospasm and peripheral vasoconstriction, making them less suitable for HFrEF management. **High-Yield:** Carvedilol, metoprolol succinate (extended-release only), and bisoprolol are the ONLY three β-blockers with proven mortality benefit in HFrEF—memorize these three for board exams and clinical practice. [cite: KD Tripathi 9e Ch 10; Harrison 21e Ch 252]